Medication availability and economic barriers to adherence in asthma and COPD patients in low-resource settings

Aizhamal Tabyshova1,2,3, Talant Sooronbaev2, Azamat Akylbekov2, Maamed Mademilov2, Aida Isakova4, Aidai Erkinbaeva5, Kamila Magdieva5, Niels H. Chavannes6, Maarten J. Postma1,7,8,9 and Job F. M. van Boven1,10

Inhaled medication is essential to control asthma and COPD, but availability and proper adherence are challenges in low-middle income countries (LMIC). Data on medication availability and adherence in Central Asia are lacking. We aimed to investigate the availability of respiratory medication and the extent of financially driven non-adherence in patients with COPD and asthma in Kyrgyzstan. A cross-sectional study was conducted in two regions of Kyrgyzstan. Patients with a physician- and spirometry confirmed diagnosis of asthma and/or COPD were included. The main outcomes were (1) availability of respiratory medication in hospitals and pharmacies, assessed by a survey, and (2) medication adherence, assessed by the Test of Adherence to Inhalers (TAI). Logistic regression analyses were used to identify predictors for adherence. Of the 300 participants (COPD: 264; asthma: 36), 68.9% were buying respiratory medication out-of-pocket. Of all patients visiting the hospital, almost half reported medication not being available. In pharmacies, this was 8%. Poor adherence prevailed over intermediate and good adherence (80.7% vs. 12.0% and 7.3%, respectively). Deliberate and erratic non-adherence behavior patterns were the most frequent (89.7% and 88.0%), followed by an unconscious non-adherent behavioral pattern (31.3%). In total, 68.3% reported a financial reason as a barrier to proper adherence. Low BMI was the only factor significantly associated with good adherence. In this LMIC population, poor medication availability was common and 80% were poorly adherent. Erratic and deliberate non-adherent behaviors were the most common pattern and financial barriers play a role in over two-thirds of the population.

npj Primary Care Respiratory Medicine (2022) 32:20; https://doi.org/10.1038/s41533-022-00281-z

INTRODUCTION

Worldwide, COPD and asthma are the most prevalent chronic respiratory diseases placing a significant clinical and economic burden on patients and societies1. Notably, the burden of chronic respiratory diseases seems disproportionately high in low- and middle-income countries (LMIC)2,3. Importantly, the higher the control of asthma and COPD and the lower their exacerbation rate, the lower the level of health care expenditures on these diseases4,5.

To control asthma and COPD, effective inhaled respiratory medicines have been developed and are widely recommended in clinical guidelines6,7. These medicines may however not all be available in all global settings, especially in LMIC. The World Health Organization (WHO) has developed the Essential Medicines List (EML), a list of essential medicines to help countries choose medicines that improve health and lower costs8. A survey of 32 LMIC indicated that over 90% had national EMLs in place9. While national EMLs aim to support the availability of a minimum number of respiratory drugs, actual, real-world, availability in LMIC is often much lower. Indeed, in LMIC, the availability of medicines for asthma was only 30.1% and 43.1%, in private and public sectors respectively10. An earlier study also found that the availability of three cornerstone asthma drugs (beclomethasone, budesonide, and salbutamol) in 52 LMIC was poor across treatment centers and hospitals11. More recently, a Ugandan study demonstrated that the majority of asthma and COPD medicines were largely unavailable, especially in public hospitals, and were unaffordable in the private sector12.

In addition, even when some medication may be available in LMIC, financial barriers may hamper proper adherence to inhalers in asthma and COPD patients. A significant association was found between non-adherence and poor disease outcomes (e.g., exacerbations), and greater health-economic burden (e.g., direct and indirect health care costs)13,14. Previous studies have shown that non-adherence can occur due to a number of reasons with cost-related reasons being an important one in high resource settings, with medicines potentially being considered not cost-effective15. The extent to which economic barriers play a role in medication non-adherence in LMIC is unknown. Assessing adherence to asthma/COPD medication has long been difficult to perform in LMIC settings given the lack of validated measurement methods. Especially for LMIC in the Central Asian region, limited data on medication availability and adherence has been published. Recently, the “Test of Adherence to Inhalers” (TAI) for asthma and COPD patients was developed, which potentially could provide required insights, also in LMIC. The TAI is a validated questionnaire to identify non-adherence and to assess barriers...
related to the use of inhalers in asthma and COPD, including financial reasons.\textsuperscript{16}

The aim of this study is to describe availability of respiratory drugs and the extent of financially driven non-adherence in patients with COPD and asthma in a LMIC, taking Central Asian country Kyrgyzstan as a case study.

METHODS
Study design
This was a cross-sectional study that was conducted from June 2021 to July 2021. We used questionnaires in a representative sample of patients with asthma and COPD. Ethical approval was obtained from the ethical committee of the National Center of Cardiology and Internal Medicine (NCCIM) with protocol number 4. The study is reported according to the STROBE checklist for cross-sectional studies (Supplementary Information).

Setting
The study was conducted in two regions of Kyrgyzstan. Kyrgyzstan is a land-locked, mountainous lower-middle income country in Central Asia with, according to the Worldbank, a gross domestic product per capita of $1178 in 2020. The regions were Jalal-Abad and Chui (Bishkek). In the city of Jalal-Abad, patients were recruited in the primary health care center and at the pulmonology department of the Jalal-Abad regional hospital, and in Bishkek patients were recruited from several randomly selected primary health care centers.

Participants
We included patients with asthma and COPD fulfilling the following inclusion and exclusion criteria.

Inclusion criteria:

- Age \( \geq \) 18 years
- Born and live in Kyrgyzstan and speaking Russian and/or Kyrgyz
- Physician confirmed diagnosis of asthma/COPD
- COPD: FEV\(_1\)/FVC ratio < 0.7
- Asthma: Post-bronchodilator increase in FEV\(_1\) > 12% or 200 ml from baseline
- Patient consent to participate and willing to sign the consent form

Exclusion criteria:

- FEV\(_1\)/FVC ratio \( > 0.7 \) in COPD patients
- No reversibility after bronchodilator test in asthma patients
- Patients that have a disability in communication

Data sources
For this study, multiple primary (i.e., a patient questionnaire) and secondary data (i.e., clinical record data from the branches of primary health care centers) sources were used. The questionnaire was developed by the research team, piloted among a small group, and optimized before large-scale data collection. The collecting process for the patient questionnaires is described below. As part of our Data Management Plan, only anonymized data were shared between study site collaborators and the research team, limiting data to the part that was kept securely taking the participant’s privacy into consideration.

Data collecting process
Data collection was performed by the study site collaborators who were healthcare workers at the Respiratory Department of each hospital. To minimize bias in the selection of patients, every third diagnosed COPD/asthma patient from the pulmonologist registries was selected and contacted by phone by one of the study site collaborators to invite them (asking them to bring all the medication they use).

Firstly, study site collaborators introduced the meaning and target of the study to patients and then invited them to take part in the study.

Secondly, if patients agreed (and signed the informed consent that was written in the questionnaire, see Supplementary Information) the diagnosis was confirmed. In patients who did not have spirometry in their case-record, spirometry was performed for confirmation.

Afterwards, patients received the survey; patients did the survey by themselves with help from the study site collaborators if needed. In case of misunderstanding of any questions, collaborators helped to explain them.

Finally, when patients finished their survey and submitted it to the study site collaborators, collaborators checked it for detecting any missing answers or mistakes and asked them to correct it.

Data to be collected
The Test of Adherence to Inhalers (TAI) (Supplementary Information) was used to identify problems with adherence to inhalation therapy. The TAI is a validated questionnaire consisting of 10 items (with a scale of 1–5) to be completed by the patient and two questions (with a scale of 1–2) to be completed by a healthcare professional. In this study, we used the formally translated Russian version of the TAI as available from www.taitest.com. The total score is 50 for the 10-item TAI and 54 for the 12-item TAI. The TAI distinguishes good adherence (TAI-10 = 50), intermediate adherence (TAI-10 = 46–49), and poor adherence (TAI-10 < 46). In addition, the type of non-adherence can be assessed including erratic (sum of TAI questions 1–5: <25), deliberate (sum of TAI questions 6–10: <25) and unconscious non-adherence (sum of TAI questions 11–12: <4). We had particular interest in TAI question 10 that focuses on financial barriers for non-adherence\textsuperscript{16}. Medication availability in hospitals, private clinics, and pharmacies as well as having received a straightforward technique training instruction on inhaler use was assessed by a patient survey that also included several baseline characteristics (Supplementary Information).

Outcomes
The main study outcomes were (1) availability of respiratory medication and inhaler training in the hospital, community pharmacy, and private clinic, as measured by the survey, and (2) adherence to respiratory medication, as measured with TAI questionnaire. Of the two outcomes, the availability of medication is a health system barrier for which we expected little impact of patient-related co-variables. For the other outcome, i.e., medication adherence, we hypothesized that some patient co-variates may impact this. Therefore, several predefined demographic (e.g., age, sex, education, work status), clinical (e.g., disease severity, comorbidities), pharmaceutical (daily regimen), and socioeconomic (e.g. monthly income, self-buying of medication) predictors for non-adherence were collected based on literature and the authors’ experience (Supplementary Information).

Statistical methods and sample size
Descriptive statistics (mean, median, SD, minimum, maximum) and the Chi-square test were used for the comparison of categorical variables. Univariable and multivariable regression
Table 1. Sociodemographic and clinical characteristics of asthma and/or COPD participants (n = 300).

| Variable                        | All (n = 300) | COPD group (n = 264) | Asthma group (n = 36) |
|---------------------------------|---------------|----------------------|-----------------------|
| **Age, y**                      |               |                      |                       |
| Mean (SD)                       | 58.5 (11.8)   | 59.8 (10.8)          | 49.1 (14.5)           |
| Median (minimum; maximum)       | 60 (19; 100)  | 61 (19; 100)         | 49 (21; 77)           |
| **Sex**                         |               |                      |                       |
| Male, No. (%)                   | 171 (57.0)    | 157 (59.5)           | 14 (38.9)             |
| Female, No. (%)                 | 129 (43.0)    | 107 (40.5)           | 22 (61.1)             |
| **BMI, kg/m²**                  |               |                      |                       |
| Mean (SD)                       | 28.2 (6.2)    | 28 (5.9)             | 29.4 (7.9)            |
| Median (minimum; maximum)       | 27.7 (16.2; 99.3) | 27.6 (18; 93.3) | 29 (16.2; 59.3) |
| **Monthly income, USD$**        |               |                      |                       |
| Mean (SD)                       | 128.9 (113.2) | 127.2 (109.6)        | 142 (138.5)           |
| Median (minimum; maximum)       | 98.5 (0; 944.3) | 94.4 (0; 944.3)  | 118 (0; 802.6)        |
| **Missing value**               | 6             | 5                    | 1                     |
| **Education**                   |               |                      |                       |
| Primary/secondary, No. (%)      | 84 (28.2)     | 73 (27.9)            | 11 (30.6)             |
| Professional, No. (%)           | 127 (42.3)    | 110 (42.0)           | 17 (47.2)             |
| University, No. (%)             | 87 (29.2)     | 79 (30.2)            | 8 (22.2)              |
| **Working status**              |               |                      |                       |
| Working, No. (%)                | 126 (42.0)    | 110 (41.7)           | 16 (44.4)             |
| Unemployed, No. (%)             | 49 (16.3)     | 39 (14.8)            | 10 (27.8)             |
| Retired, No. (%)                | 125 (41.7)    | 115 (43.6)           | 10 (27.8)             |
| Having insurance, No. (%)       | 297 (99.0)    | 261 (98.9)           | 36 (100.0)            |
| **Missing value**               | 3             | 3                    | –                     |
| **Smoking status**              |               |                      |                       |
| Current smoker, No. (%)         | 50 (16.7)     | 46 (17.4)            | 4 (11.1)              |
| Ex-smoker, No. (%)              | 94 (31.3)     | 85 (32.2)            | 9 (25.0)              |
| Never smoker, No. (%)           | 156 (52.0)    | 133 (50.4)           | 23 (63.9)             |
| **Biomass using for heating/cooking, No. (%)** | 145 (48.3) | 131 (49.6) | 14 (38.9) |
| Yes                             |               |                      |                       |
| No                              | 155 (51.7)    | 133 (50.4)           | 22 (61.1)             |
| **Disease duration, years**     |               |                      |                       |
| Mean (SD)                       | 9.8 (6.4)     | 9.7 (6.5)            | 10.6 (5.9)            |
| Median (minimum; maximum)       | 10 (1; 40)    | 10 (1; 40)           | 10 (1; 20)            |
| **Pulmonary function tests**    |               |                      |                       |
| FEV₁, % predicted               |               |                      |                       |
| Mean (SD)                       | 53.5 (14.9)   | 53.4 (15.4)          | 53.7 (10.9)           |
| Median (minimum; maximum)       | 55 (18; 83)   | 55 (18; 83)          | 55 (34; 72)           |
| FEV₁/FVC ratio, %               |               |                      |                       |
| Mean (SD)                       | 59 (11.0)     | 58.2 (8.5)           | 65.6 (21.3)           |
| Median (minimum; maximum)       | 60 (0; 83.4)  | 60 (30.5; 83.4)      | 72 (0; 83)            |
| Reversibility, %                |               |                      |                       |
| Mean (SD)                       | –             | –                    | 23.2 (10.0)           |
| Median (minimum; maximum)       | –             | –                    | 18.5 (9; 48)          |
| **COPD, GOLD grade, No. (%)**   |               |                      |                       |
| GOLD 1                          | –             | 3 (1.0)              | –                     |
| GOLD 2                          | –             | 160 (60.6)           | –                     |
| GOLD 3                          | –             | 79 (29.9)            | –                     |
| GOLD 4                          | –             | 22 (8.3)             | –                     |
| **Comorbidities**               |               |                      |                       |
| Cardiovascular diseases, No. (%)|               |                      |                       |
| Allergic rhinitis, No. (%)      |               |                      |                       |
| Bronchiectasis, No. (%)         |               |                      |                       |
| Diabetes, No. (%)               |               |                      |                       |
| Depression, No (%)              |               |                      |                       |
| Co-medications                  |               |                      |                       |
| 0 co-medication, No (%)         |               |                      |                       |
| 1 co-medication, No (%)         |               |                      |                       |
| 2 co-medications, No (%)        |               |                      |                       |
| ≥3 co-medications, No (%)       |               |                      |                       |
| **Type of prescribed medication**|               |                      |                       |
| SABA                            |               |                      |                       |
| SABA/SAMA                       |               |                      |                       |
| LAMA                            |               |                      |                       |
| LABA                            |               |                      |                       |
| ICS/LABA                        |               |                      |                       |
| MCS                             |               |                      |                       |
| Antibiotics                     |               |                      |                       |
| **Number of times taking respiratory medication per day** | | | |
| 1 time, No (%)                  |               |                      |                       |
| 2 times, No (%)                 |               |                      |                       |
| 3 times, No (%)                 |               |                      |                       |
| 4 times, No (%)                 |               |                      |                       |
| 5 times, No (%)                 |               |                      |                       |
| **Missing value**               | 1             | 1                    | –                     |
| **Buying respiratory medication, No (%)** | 206 (68.9) | 184 (70.0) | 22 (61.1) |
| Myself                          |               |                      |                       |
| Partly covered by health insurance | 84 (28.1) | 72 (27.4) | 12 (33.3) |
| Fully covered by health insurance | 9 (3.0) | 7 (2.7) | 2 (5.6) |
| **Co-payment for the drugs, mean (SD)** | 8.3 (8.2) | 7.9 (8.0) | 10.5 (9.0) |
| Formal, USD$                    | 2.1 (4.8)     | 1.6 (3.5)            | 5.3 (9.5)             |

Table 1 continued

| Variable                        | All (n = 300) | COPD group (n = 264) | Asthma group (n = 36) |
|---------------------------------|---------------|----------------------|-----------------------|
| **ACO, No. (%)**                | 11 (3.7)      | –                    | –                     |
| **Co-medications**              |               |                      |                       |
| 0 co-medication, No (%)         |               |                      |                       |
| 1 co-medication, No (%)         |               |                      |                       |
| 2 co-medications, No (%)        |               |                      |                       |
| ≥3 co-medications, No (%)       |               |                      |                       |
| **Type of prescribed medication**|               |                      |                       |
| SABA                            |               |                      |                       |
| SABA/SAMA                       |               |                      |                       |
| LAMA                            |               |                      |                       |
| LABA                            |               |                      |                       |
| ICS/LABA                        |               |                      |                       |
| MCS                             |               |                      |                       |
| Antibiotics                     |               |                      |                       |

Analyses were used to assess associations between predictors and the outcomes (i.e. proper medication adherence, defined as a 10-item TAI score >45). Anticipating to a degree of non-adherence of 50%17, a regression model with 15 potential predicting variables for non-adherence and the estimated requirement of 10 events of non-adherence per variable in logistic regression analysis14,15, we aimed for the inclusion of 300 patients. Variables with p < 0.25 in

Published in partnership with Primary Care Respiratory Society UK

npj Primary Care Respiratory Medicine (2022) 20
Population characteristics

In total, the study included 300 participants, of which 264 patients with COPD and 36 patients with asthma. In Table 1, the sociodemographic and clinical characteristics of the study population are shown. The majority of the participants were male (57.0%), with a mean age of 58.5 (SD = 11.8) years, mostly with professional educational level (42.3%), active working status (42.0%), never smokers (52.0%) and using biomass for heating/cooking (48.3%). The mean duration of asthma/COPD was 9.8 (SD = 6.4) years. More than half of the participants had moderate COPD (60.6%), i.e., GOLD II. The most frequent comorbidities were cardiovascular diseases (48.0%) and allergic rhinitis (16.3%). Twenty percent used ≥3 co-medications. Short-acting muscarinic antagonists (SAMA), short-acting beta agonists (SABA), and inhaled corticosteroids/long-acting beta agonists (ICS/LABA) were the most frequently prescribed inhalers (57.2, 37.3, and 12.7%). Only 1.0% of patients used a long-acting muscarinic antagonist (LAMA), due to unavailability and unaffordability. Of note, 68.9% of the patients were buying respiratory medication from their own pocket. Most of them (38.8%) used respiratory medication four times per day.

Adherence to inhalers, adherence level and non-adherence behavior patterns in asthma and/or COPD patients.

Table 3.

| Variable                             | All (n = 300) | COPD group (n = 264) | Asthma group (n = 36) |
|--------------------------------------|---------------|----------------------|-----------------------|
| Adherence level (10-item TAI)        |               |                      |                       |
| Good                                 | 22 (7.3)      | 22 (8.3)             | 0 (0.0)               |
| Intermediate                         | 36 (12.0)     | 28 (10.6)            | 8 (22.2)              |
| Poor                                 | 242 (80.7)    | 214 (81.1)           | 28 (77.8)             |
| Non-adherence behavior (12-item TAI) |               |                      |                       |
| Erratic                              | 264 (88.0)    | 231 (87.5)           | 33 (91.7)             |
| Deliberate                           | 269 (89.7)    | 235 (89.0)           | 34 (94.4)             |
| Unconscious                          | 94 (31.3)     | 80 (30.3)            | 14 (38.9)             |

Data as frequencies and percentages in parenthesis. TAI test of adherence to inhalers.

Availability of respiratory medication

Table 2 shows the availability of respiratory medication and inhaler technique education. Of all patients that visited the hospital, almost half reported that medication was not available. For the pharmacy, this was the case in 8%. Around a third of the respondents visited a private clinic, yet medication was mostly not available. There was no any difference in availability for respiratory drugs between Bishkek and Jalal-Abad patients. Almost all study participants were trained to use respiratory inhalers, either by a doctor (90%), a pharmacist (6.3%), a nurse (2.3%), and only 1.3% was never trained.

Adherence to respiratory medication

Adherence to inhalers was evaluated with the TAI questionnaire (Table 3). When assessing the 10-item TAI level of adherence in the total population, it was found that poor adherence prevailed over intermediate and good adherence (80.7% vs. 12.0% and 7.3%), with similar patterns observed in the asthma and COPD groups. The 12-item TAI revealed that the deliberate and erratic non-adherence behavior patterns were the most frequent (89.7% and 88.0%), followed by the unconscious behavior pattern (31.3%).

As shown in Fig. 1, erratic behavior combined with deliberate behavior (84.7%) was more frequent than other combinations: erratic with unconscious (30.3%), deliberate with unconscious (29.7%), and erratic with deliberate and unconscious (29.0%), among which the difference was only a fraction of units.

Of the individual barriers to medication adherence, stopping taking inhalers after the symptoms improve, deliberately reducing the number of inhalers prescribed by the doctor and forgetfulness were the TAI questions with the lowest scores (Fig. 2). Of all patients, 205 (68.3%) reported a financial reason (i.e., TAI question 10 score <5) to be a barrier to proper adherence.

Associations with good adherence

The study population was distributed according to proper adherence (good or intermediate, defined as 10-item TAI > 45, i.e., N = 58) or non-adherence (poor, defined as 10-item TAI < 46, i.e., N = 242). In the multivariate regression analysis in the total population, having a low BMI was the only factor significantly associated with proper adherence (1.893, 95% CI 1.015–3.530). Male gender (1.235, 95% CI 0.656–2.327), low income (1.825, 95% CI 0.598–5.576), being unemployed (1.962, 95% CI 0.850–4.528), having allergic rhinitis (1.884, 95% CI 0.874–4.060), and previously trained in inhalation technique by a physician (5.576, 95% CI 1.086–29.700) were positively yet non-significantly associated with proper adherence (Table 4).

Buying medication by the patient him or
herself (0.641, 95% CI 0.340–1.208) and having to use medication more than two times per day (0.665, 95% CI 0.352–1.255) was negatively but non-significantly associated with proper adherence. Subgroup analyses in patients with either asthma or COPD showed similar patterns (Supplementary Information).

**DISCUSSION**

In this study performed in a lower-middle income country, almost half of all asthma/COPD patients reported that medication was not available in the hospital. For the pharmacy, this was the case in 8%. Around 80% of the participants were poorly adherent. Erratic and deliberate non-adherent behavior were the most commonly observed patterns. Low BMI was the only factor significantly and positively associated with proper adherence in multivariable analyses. Male gender, low income, unemployed, having allergic rhinitis, and previously trained in inhalation technique by a physician were related with proper adherence but not significantly. Buying medication by the patient him or herself and having to use the medication more than two times per day was negatively but non-significantly associated with adherence. In addition, 68.3% of patients reported financial reasons as a barrier to good adherence. Regarding availability of respiratory medication, previously Zurdinova et al. reported that there were problems with the availability of inhaled medication in Kyrgyzstan. Inhaled corticosteroids (ICS) were only available for sale in Kyrgyz capital Bishkek and not in other regions. From the group of bronchodilators, only salbutamol and astalin were available all throughout Kyrgyzstan\(^2\). This seems reflected in our study with still the majority using short-acting medication (COPD: mostly short-acting muscarinic antagonists; asthma: mostly short-acting beta agonists) and only one third using long-acting medication (including ICS, which are now the first choice according to GINA). Importantly, of all COPD pharmacotherapy, only bronchodilators are economically affordable (in the range of the affordability coefficient from 0.1 to 0.4). ICS and fixed combinations of bronchodilators remain economically unaffordable (in the range of the affordability coefficient from 1.7 to 4)\(^2\). Indeed, previously we have shown that co-payments for COPD treatment in LMIC Kyrgyzstan can take up around 22% of patients’ annual income\(^2\). In the present study, there was no difference in the availability of respiratory medication between patients treated in Bishkek and Jalal-Abad. A positive finding was that for the patients who had medication available, almost all study participants were trained
Table 4. Univariate and multivariate association with adherence in asthma and COPD patients (n = 300).

| Variable                                      | Univariate OR     | p-value | Multivariate OR    | p-value* |
|-----------------------------------------------|-------------------|---------|--------------------|----------|
| Age                                          |                   |         |                    |          |
| ≤50 years                                     | 1.463 (95% CI 0.760–2.815) | 0.255   |                    |          |
| >50 years                                     | Reference group   |         |                    |          |
| Sex                                           |                   |         |                    |          |
| Male                                          | 1.420 (95% CI 0.785–2.568) | 0.246   | 1.235 (95% CI 0.656–2.327) | 0.513    |
| Female                                        | Reference group   |         |                    |          |
| BMI                                           |                   |         |                    |          |
| Low BMI                                       | 1.777 (95% CI 0.988–3.198) | 0.055   | 1.893 (95% CI 1.015–3.530) | 0.045*   |
| High BMI                                      | Reference group   |         |                    |          |
| Monthly income                                |                   |         |                    |          |
| Low income                                    | 1.484 (95% CI 0.827–2.661) | 0.186   | 1.825 (95% CI 0.598–5.576) | 0.291    |
| High income                                   | Reference group   |         |                    |          |
| Education                                     |                   |         |                    |          |
| Primary/secondary                             | 1.044 (95% CI 0.484–2.252) | 0.912   |                    |          |
| Professional                                  | 1.088 (95% CI 0.542–2.183) | 0.813   |                    |          |
| University                                    | Reference group   |         |                    |          |
| Working status                                |                   |         |                    |          |
| Working                                       | 0.887 (95% CI 0.462–1.701) | 0.718   |                    |          |
| Unemployed                                    | 1.774 (95% CI 0.824–3.821) | 0.143   | 1.962 (95% CI 0.850–4.528) | 0.114    |
| Retired                                       | Reference group   |         |                    |          |
| Smoking status                                |                   |         |                    |          |
| Current smoker                                | 1.003 (95% CI 0.438–2.300) | 0.993   |                    |          |
| Ex-smoker                                     | 1.315 (95% CI 0.697–2.481) | 0.398   |                    |          |
| Never smoker                                  | Reference group   |         |                    |          |
| Biomass using for heating/cooking             |                   |         |                    |          |
| Yes                                           | 1.298 (95% CI 0.729–2.313) | 0.376   |                    |          |
| No                                            | Reference group   |         |                    |          |
| Disease duration                              |                   |         |                    |          |
| >10 years                                     | Reference group   |         |                    |          |
| <10 years                                     | 1.415 (95% CI 0.779–2.571) | 0.255   |                    |          |
| Pulmonary function tests                      |                   |         |                    |          |
| FEV1, % Predicted                             |                   |         |                    |          |
| <52                                           | Reference group   |         |                    |          |
| >52                                           | 1.104 (95% CI 0.618–1.974) | 0.738   |                    |          |
| FEV1/FVC ratio, %                             |                   |         |                    |          |
| <59                                           | Reference group   |         |                    |          |
| >59                                           | 1.058 (95% CI 0.593–1.887) | 0.850   |                    |          |
| COPD, GOLD grade                              |                   |         |                    |          |
| GOLD 1–2                                      | Reference group   |         |                    |          |
| GOLD 3                                        | 1.081 (95% CI 0.551–2.122) | 0.820   |                    |          |
| GOLD 4                                        | 0.997 (95% CI 0.464–2.140) | 0.993   |                    |          |
| Comorbidities                                 |                   |         |                    |          |
| Cardiovascular diseases                       | 0.854 (95% CI 0.480–1.518) | 0.590   |                    |          |
| Allergic rhinitis                             | 2.134 (95% CI 1.070–4.257) | 0.031*  | 1.884 (95% CI 0.874–4.060) | 0.106    |
| Diabetes                                      | 0.819 (95% CI 0.299–2.239) | 0.697   |                    |          |
| Buying respiratory medication                 |                   |         |                    |          |
| Myself                                        | 0.568 (95% CI 0.314–1.028) | 0.062   | 0.641 (95% CI 0.340–1.208) | 0.169    |
| Partly/fully covered by health insurance      | Reference group   |         |                    |          |
| Previous inhaler education                    |                   |         |                    |          |
| By doctor                                     | 7.761 (95% CI 1.035–58.197) | 0.046*  | 6.868 (95% CI 0.895–52.691) | 0.064    |
| By nurse/pharmacist/Never                     | Reference group   |         |                    |          |
| Number of times taking medication per day     |                   |         |                    |          |
| 1–2 times                                     | Reference group   |         |                    |          |
| >2 times                                      | 0.578 (95% CI 0.322–1.036) | 0.066   | 0.665 (95% CI 0.352–1.255) | 0.208    |

BMI body mass index, FEV1 forced expiratory volume in 1 s, COPD chronic obstructive pulmonary disease, GOLD The Global Initiative for Obstructive Lung Disease.

* p < 0.05; High BMI is >27.7 (median), Low BMI is <27.7 (median); High monthly income is >98.5 USD$ (median), Low monthly income is <98.5 USD$ (median). Missing variables: Monthly income –6; Education –2; Buying respiratory medication –1; Number of times taking medication per day –1.
found that adherence was significantly higher for once-daily versus multiple dosing regimens. This study was the first investigating adherence in spirometry-confirmed COPD and asthma patients in a LMIC setting using the validated TAI questionnaire. The TAI questionnaire was not used in Kyrgyzstan before. The present research focused on barriers for adherence in LMIC, and was the first for Central Asia. Limitations include the fact that the number of patients with COPD and asthma was different and not comparable and therefore patients were analyzed together in the regression analyses. In addition, no disease control questionnaire was included while this may have been a predicting factor for adherence. Regarding the unintentional non-adherence aspect, the patients knew that their inhalation technique was evaluated, which could introduce bias. Also, the TAI questionnaire is not used in current daily Kyrgyz asthma/COPD management and they may therefore not be familiar with the type of questions.

Adherence to medication in COPD and asthma is important for clinical success, and non-adherence is a significant health and economic burden all over the world. Several simple methods can be applied to address this problem: using simplified medication regimens, increasing the patient’s knowledge of self-management, and improving the health care workers in patient education and adherence counseling. Smart inhalers have already been created, which are not yet used in practice, but have already yielded good results regarding monitoring and managing medication adherence, however, more research is needed. It is important to note that there is a large shortage of primary health care workers, especially in more remote Kyrgyz regions, and due to the heavy workload of physicians, they physically do not have time or forget to evaluate or support patients’ adherence. Policy makers should focus on medication availability and affordability, increasing the primary health care workforce, and increasing awareness of patients on medication adherence. More research and interventions are needed to improve medication adherence in Kyrgyzstan and other LMIC. While the availability of inhaled respiratory varied by facility, around 80% of patients in this LMIC population were poorly adherent. Erratic and deliberate non-adherent behaviors were the most common pattern and financial barriers play a role in 68.3% of the population.

DATA AVAILABILITY

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 28 September 2021; Accepted: 5 April 2022; Published online: 30 May 2022

REFERENCES

1. Soriano, J. B. et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir. Med. 8, 585–596 (2020).
2. Beran, D., Zar, H. J., Perrin, C., Menezes, A. M. & Burney, P. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir. Med. 3, 159–170 (2015).
3. Brakema, E. A. et al. FRESH AIR collaborators. The socioeconomic burden of chronic lung disease in low-resource settings across the globe - an observational FRESH AIR study. Respir. Res. 20, 291 (2019).
4. Sullivan, P. W. et al. Measuring the cost of poor asthma control and exacerbations. J. Asthma 54, 24–31 (2017).
5. Lee, L. K., Obi, E., Palniss, B., Kavati, A. & Chipp, B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J. Asthma 55, 208–219 (2018).
6. Singh, D. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur. Respir. J. 53, 1900164 (2019).
7. Tabayshova, A. et al. Gaps in COPD Guidelines of Low- and Middle-Income Countries: A Systematic Scoping Review. *Chest* 159, 575–84 (2021).

8. WHO Model List of Essential Medicines (21st list). [https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf) (2019).

9. Bazargani, Y. T., de Boer, A., Leufkens, H. G. M. & Mantel-Teeuwisse, A. K. Essential medicines for COPD and asthma in low and middle-income countries. *Thorax* 69, 1149–51 (2014).

10. Bissell, K., Perrin, C. & Beran, D. Access to essential medicines to treat chronic respiratory disease in low-income countries. *Int J. Tuberc. Lung Dis.* 20, 717–728 (2016).

11. Babar, Z. U., Lessing, C., Mace, C. & Bissell, K. The availability, pricing and affordability of three essential asthma medicines in 52 low and middle-income countries. *Pharmacoconomics* 31, 1063–1082 (2013).

12. Kibirige, D. et al. Access to affordable medicines and diagnostic tests for asthma and COPD in sub-Saharan Africa: the Ugandan perspective. *BMJ Pulm. Med.* 17, 179 (2017).

13. Usmani, O. S. et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. *Respir. Res.* 19, 10 (2018).

14. Mäkelä, M. J., Backer, V., Hedegaard, M. & Larsson, K. Adherence to inhaled therapies: health outcomes and costs in patients with asthma and COPD. *Respir. Med.* 107, 1481–1490 (2013).

15. Laba, T. L. et al. Cost-related underuse of medicines for asthma-opportunities for action. [https://apps.who.int/iris/handle/10665/42682](https://apps.who.int/iris/handle/10665/42682) (2003).

16. Plaza, V. et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for asthma and COPD patients. *J. Aerosol Med. Pulm. Drug Deliv.* 29, 142–152 (2016).

17. World Health Organization. Adherence to long-term therapies: evidence for a clinical, economic and policy agenda. *https://apps.who.int/iris/handle/10665/42682* (2003).

18. Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. & Feinstein, A. R. A simulation study of the number of events per variable in logistic regression analysis. *J. Clin. Epidemiol.* 49, 1373–1379 (1996).

19. Bursac, Z., Gauss, C. H., Williams, D. K. & Hosmer, D. W. Purposeful selection of variables in logistic regression. *Source Code Biol. Med.* 3, 17 (2008).

20. Zundrova, A. et al. Scientific justification of rational pharmacotherapy in the development and implementation of clinical guidelines based on the principles of evidence medicine. *Dissertation. 615.084:001:616-071:616(02)* (2018).

21. Tabayshova, A. et al. Clinical characteristics, treatment patterns and economic burden of COPD in Kyrgyzstan: a FRESH AIR study. *Int. J. Chron. Obstruct. Pulmon. Dis.* 16, 2833–2843 (2021).

22. Klijn, S. L. et al. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. *NPJ Prim. Care Respir. Med.* 27, 24 (2017).

23. Ahn, J. H. et al. The effects of repeated inhaler device handling education in COPD patients: a prospective cohort study. *Sci. Rep.* 10, 19676 (2020).

24. Takemura, M. et al. Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease. *Int J. Chron. Obstruct. Pulmon. Dis.* 6, 97–104 (2011).

25. Plaza, V. et al. Differences in adherence and non-adherence behaviour patterns to inhaler devices between COPD and asthma patients. *COPD: J. Chronic Obstr. Pulm. Dis.* 13, 547–554 (2016).

26. Vestbo, J. et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. *Thorax* 64, 939–943 (2009).

27. Āgh, T., Inotai, A. & Mészáros, Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. *Respiration* 82, 328–334 (2011).

28. Darbá, J., Ramirez, G., Sicras, A., Francoli, P. & Torvinen, S. Sánchez-de la Rosa, R. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. *Int. J. Chron. Obstruct. Pulmon. Dis.* 10, 2319–2345 (2015).

29. Elander, A. G. M. Inhaler technique and self-reported adherence to medications among hospitalised people with asthma and COPD. *Drugs Real. World Outcomes* 7, 317–23 (2020).

30. López-Campos, J. L., Quintana Gallego, E. & Carrasco Hernández, L. Status of and strategies for improving adherence to COPD treatment. *Int. J. Chron. Obstruct. Pulmon. Dis.* 14, 1503–15 (2019).

31. Corden, Z. M., Bosley, C. M., Rees, P. J. & Cochrane, G. M. Home nebulized therapy for patients with COPD: patient compliance with treatment and its relation to quality of life. *Chest* 112, 1278–1282 (1997).

32. Krigsman, K., Moen, J., Nilsson, J. L. & Ring, L. Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period. *J. Clin. Pharm. Ther.* 32, 603–611 (2007).

33. Apt, A. J., Reisine, S. T., Affleck, G., Barrows, E. & ZuWallack, R. L. Adherence with twice-daily dosing of inhaled steroids. *Socioeconomic and health-belief differences. Am. J. Respir. Crit. Care Med.* 157, 1810–1817 (1998).

34. Duarte-de-Araújo, A., Teixeira, P., Hespanhol, V. & Correia-de-Sousa, J. COPD: understanding patients’ adherence to inhaled medications. *Int. J. Chron. Obstruct. Pulmon. Dis.* 13, 2767–73 (2018).

35. Claxton, A. J., Cramer, J. & Pierce, C. A systematic review of the associations between dose regimens and medication compliance. *Clin. Ther.* 23, 1296–310 (2001).

36. van de Hei, S. J., Dierick, B. J. H., Aarts, J. E. P., Kocks, J. W. H. & van Boven, J. F. M. Personalized medication adherence management in asthma and chronic obstructive pulmonary disease: a review of effective interventions and development of a practical adherence toolkit. *J. Allergy Clin. Immunol. Pract.* 9, 3979–3994 (2021).

37. Jansen, E. M. et al. Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers. *J. Thorac. Dis.* 13, 3846–3864 (2021).

**ACKNOWLEDGEMENTS**

This study was not funded. We thank Ayzada Palvanova (Jalal-Abad Regional Hospital, Jalal-Abad, Kyrgyzstan) for her important role in collecting data in the Southern region of Kyrgyzstan. We also thank the residents of the Pulmonology Department (National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan) for their input in the data collection process. Lastly, we thank all participants.

**AUTHOR CONTRIBUTIONS**

A.T. and J.v.B. designed the study. T.S., A.A., M.M., A.J., A.E., and K.M. carried out the data collection. A.T. performed the calculations. A.T. wrote the manuscript with input from all authors, T.S., J.v.B., and A.T. were in charge of the overall direction and planning of the study.

**COMPETING INTERESTS**

J.v.B. has received grants and/or consultancy fees from AstraZeneca, Chiesi, GSK, Novartis, Teva, and Trudell Medical, all unrelated to this study, and paid to his employer (University Medical Center Groningen). M.P. and N.C. have received funding from various pharmaceutical companies that manufacture respiratory medication, all unrelated to this study, and paid to their employer. Other authors declare no conflict of interest.

**ADDITIONAL INFORMATION**

**Supplementary information** The online version contains supplementary material available at [https://doi.org/10.1038/s41533-022-00281-z](https://doi.org/10.1038/s41533-022-00281-z).

**Correspondence** and requests for materials should be addressed to Aizhamal Tabayshova.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2022.